<DOC>
	<DOCNO>NCT02908243</DOCNO>
	<brief_summary>Primary prophylaxis severe hemophiliac define prophylaxis therapy start 2 year age prior clinically evident joint bleed first joint bleed prior onset joint damage irrespective age , joint keep normal mildly damage till teenage adulthood . Primary prophylaxis prove beneficial cause less damage joint `` on-demand '' therapy . Primary prophylaxis also know able decrease occurrence factor VIII inhibitor advance useful , cost-effective therapy hemophilia care . However , require 2 3 injection factor VIII IX 20-50 IU/Kg dos every week , cost lot expense . In year 2013 , try hard discus Bureau National Health Insurance ( BNHI ) meet couple time , eventually guideline intermediate-dose prophylaxis severe hemophilia establish consensus reach prophylactic treatment cost effective without increase burden total budget . This guideline finally approve BNHI implement July 1st , 2014 . In oder evaluate efficacy prophylaxis treatment , patient arrange come back hemophilia center least year investigation dose annual consumption clot factor , frequency cause bleeding , especially joint bleeding , joint outcome study hemophilia joint health score ( HJHS ) , hemophilia active list health-related quality life . These result collect compare intermediate-dose prophylaxis group patient demand treatment group patient . The life span hemophiliac improve remarkably recent year due sufficient adequate treatment , especially prophylaxis treatment , therefore comorbidities hemophilic population , e.g . hypertension , diabetes , hyperlipidemia cancer , etc , find prevalence close non-hemophilic population . It worth prevalence comorbidity also investigate . In addition , basic data patient include age , sex , severity , development inhibitor viral infection etc also collect analysis .</brief_summary>
	<brief_title>Outcomes Prophylaxis On-demand Treatment Severe Hemophiliacs Collection Baseline Data Hemophiliacs Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>severe hemophilia A B patient 2 year age without inhibitor female hemophilia hemophiliac patient inhibitor &gt; = 0.6 Bethesda unit ( BU )</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Primary prophylaxis</keyword>
	<keyword>Pettersson Score</keyword>
	<keyword>Joint function study</keyword>
	<keyword>Comorbidity</keyword>
</DOC>